September 28, 2016

FluoroPharma announces CardioPET Phase II results at the ASNC meeting

FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that data from its Phase II clinical trial for CardioPET were presented at the 21st Annual Meeting of the American Society of Nuclear Cardiology on September 24th, 2016 in Boca Raton, Florida. {read more here}